Jefferies raises PT on Australia's Telix Pharma after deal with ITM Isotope Technologies

Telix Pharmaceuticals

30/09/2026 20:04

** Jefferies upgrades price target on Telix Pharmaceuticals TLX.AX to A$32 from A$30 
** Last week, co said it will acquire Germany-based ITM Isotope Technologies for an upfront consideration of $1.65 billion
** Brokerage ups TLX's FY27 EBITDA estimate by 10% and FY28 EBITDA estimate by 30%
** 12 of 13 analysts rate the stock "buy" or higher, 1 "hold"; their median PT is A$22, according to data compiled by LSEG 
** Stock up 40.4% YTD as of last close

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)
 ((Jasmeenaraislam.Shaikh@thomsonreuters.com))